FDA Panel Backs Novartis Drug For Treating Parkinson’s Dementia
Reviewed By
Rating
FDA Panel Backs Novartis Drug For Treating Parkinson’s Dementia
Our Review Summary
The story reports that an FDA advisory panel recommended an existing drug (rivastigmine) be approved for a new use – the treatment of dementia in people with Parkinson’s disease. The story adequately tells readers that the drug is not new, but is being considered for a new purpose. It doesn’t seem to exaggerate the condition (although more info might have been useful). However, several other areas could be improved, including discussion of costs, side effects, benefits, a description of the evidence upon which claims are based, and other treatment options. It would be a concern if this story leaves readers thinking there may be a good treatment option for Parkinson’s dementia that’s about to become available, when this may not be the case. It isn’t clear that this treatment even works in Parkinson’s, and if it does work, that any benefits are meaningful either in the short-run or long-run.
Criteria
Not Satisfactory
The story does not mention any cost information for Exelon (rivastigmine).
Not Satisfactory
The story does not quantify any benefits. What’s more, the story doesn’t give any idea what the benefits might be or what improvemements might be expected. See comments in “Evidence” section.
Not Satisfactory
The story reports the panel believes the drug to be “safe” but does not describe any side effects or harms of rivastigmine. These may include nausea/upset stomach, vomitting, loss of appetite, and headaches.
Not Satisfactory
The story does not describe any evidence for therapeutic claims that the drug works for treating Parkinson’s Disease. Additionally, it appears the FDA panel recommended approval of this drug for Parkinson’s based solely on studies from the manufacturer. Another issue is that while this drug might provide some improvement in dementia symptoms among some people with some forms of Alzheimer’s, those improvements may be small and not all people will show improvement. It’s not known whether long-term outcomes, such as nursing home admission, is improved with the drug. It’s not clear that this drug would have the same effects in a different population (those with Parkinson’s), and if so, whether those effects would be meaningful.
Satisfactory
There are no obvious elements of disease mongering. The story provides simple, straight-forward descriptions of both Alzheimer’s and Parkinson’s disease, although more information might have been useful.
Not Satisfactory
The story does not provide any independent input about the therapeutic claims of rivastigmine for treating dementia in people with Parkinson’s.
Not Satisfactory
The story does not mention other treatment options, such as memantine.
Not Satisfactory
The story fails to mention a projected date for or the next steps in obtaining FDA approval. While the FDA usually follows the advice of the advisory panel, which in this case recommended the drug’s approval for treatment of dementia associated with Parkinson’s Disease, the FDA does not have to follow the panel’s recommendation. There is no discussion of when the FDA might approve the drug for this indication.
Satisfactory
The story tells readers that the drug is currently on the market for treatment of mild to moderate Alzheimer’s disease. In other words, the story adequately reports the drug is not new, but is being considered for a new purpose.
Satisfactory
There is no obvious evidence the story relies on a press release.
Total Score: 3 of 10 Satisfactory
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like